Quantum BioPharma Ltd Dossier
Qualitative Analysis
Business overview
Quantum BioPharma Ltd. (formerly FSD Pharma Inc.) is a clinical-stage biopharmaceutical company focused on developing a portfolio of innovative assets and biotech solutions for challenging neurodegenerative, inflammatory, and metabolic disorders, as well as alcohol misuse disorders. The company operates through two primary segments: Biopharmaceutical Innovation and Strategic Investments. Its flagship drug candidate is Lucid-MS (Lucid-21-302), a patented, non-immunomodulatory new chemical entity (NCE) designed to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis (MS). Quantum also holds a 19.84% ownership stake in Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), which commercializes the over-the-counter version of UNBUZZD™, a clinically validated dietary supplement designed to accelerate alcohol metabolism.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead drug candidate Lucid-21-302 (Lucid-MS), a patented first-in-class, non-immunomodulatory, neuroprotective compound designed to prevent and reverse myelin degradation in multiple sclerosis.
Expected impact: Establishes a clinical-stage therapeutic targeting a multi-billion dollar global neurological market.
Out-licensing the over-the-counter (OTC) version of unbuzzd™, a rapid alcohol detoxification and recovery formulation, to Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.) while retaining equity and royalty rights.
Expected impact: Provides a non-dilutive revenue stream via a 7% royalty on sales up to $250 million, and 3% in perpetuity thereafter, plus potential upside from a 19.84% equity stake.
Implementing disciplined cost controls, reducing operational cash burn, and restructuring liabilities to extend the company's cash runway.
Expected impact: Reduced trade and other payables by approximately 50% (from $4.1 million to $2.0 million) and secured a cash runway extending through January 2028.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Allucent will conduct the Phase 2 clinical trial of Lucid-MS in multiple sclerosis, bringing deep expertise in CNS and complex clinical trials.
Terms: Binding Letter of Intent signed on March 30, 2026; specific financial terms were not disclosed.
Conducting a groundbreaking imaging study to evaluate brain biomarkers and therapeutic effectiveness using advanced imaging techniques.
Terms: Collaborative research agreement; specific financial terms were not disclosed.
Commercializes the OTC functional beverage unbuzzd™ in the consumer recreational sector.
Terms: Quantum BioPharma holds a 19.84% equity stake (as of Dec 31, 2025) and receives a 7% royalty on sales up to $250 million, dropping to 3% in perpetuity thereafter. Quantum also provided a $1.3 million secured loan at 10% interest.